ERβ基因衰老性甲基化对结肠癌细胞雌激素信号传导通路的表观遗传学调控的研究
|
摘要
研究目的:
了解结肠癌细胞中雌激素信号传导通路(Estrogen Signaling)的异常甲基化模式以及其与转录失活的因果关系,探讨雌激素受体β亚型基因(ERβ)对雌激素信号传导通路的表观遗传学调控方式,从不同层次上深入研究ERβ基因衰老性甲基化的表观遗传学机制及其病理意义,了解ERβ基因甲基化在结肠癌早期诊断、预防、预后评估以及治疗中的应用价值,尤其是雌激素抑制结肠肿瘤发生的作用机制,探索将此抑制作用用于已发生的肿瘤的治疗过程的应用价值和方法。
研究方法:
在整个一系列实验过程中,作为预实验部分,我们首先采用甲基化特异性PCR(MSP)方法了解了结肠癌细胞株(HT-29,Caco-2和Lovo)中ERβ及其靶基因PR(含经典的ERE元件)和c-fos原癌基因(含非经典的AP-1结合位点)启动子CpG岛的甲基化模式,采用常规PCR方法检测了结肠癌细胞株中ERβ基因、hMLH1基因、DNA甲基化转移酶1(Dnmt1)、DNA甲基化转移酶3a(Dnmt3a)、DNA甲基化转移酶3b(Dnmt3b)以及组蛋白甲基化转移酶(HMT)等表观遗传学酶谱的表达水平,为后续的研究打下基础。
在此基础上,我们采用针对ERβ基因的RNAi技术体外抑制ERβ基因的表达,观察了ERβ基因转录失活对PR和c-fos基因启动子甲基化模式的调控以及表观遗传学酶谱表达的影响;同时,采用雌激素诱导或外源性ERβ基因导入等不同手段,正向调节ERβ基因表达,观察ERβ基因表达恢复或激活对雌激素信号传导通路靶基因启动子甲基化模式的调控以及表观遗传学酶谱表达的影响。通过对ERβ基因正反两个方向的表达调节,观察除了经典的受体-配体结合方式外,ERβ基因是否还存在表观遗传学调控方式或机制。
接下来的研究中,我们采用“甲基化特异性寡核苷酸技术”,设计并合成针对ERβ基因的特异性甲基化寡核苷酸片段,作用于原代培养的雌性乳鼠结肠上皮细胞中,以诱导ERβ基因启动子发生特异性甲基化而失活,从而体外构建ERβ基因衰老性甲基化的结肠上皮细胞模型,以期模拟或者还原ERβ基因在结肠癌细胞中的表型和基因型,并在此基础上观察ERβ基因衰老性甲基化对雌激素信号传导通路的表观遗传学调控效应,深入探讨ERβ基因衰老性甲基化的表观遗传学机制及其病理意义,尤其是在雌激素预防女性结肠癌发生中可能的作用机理,为研究结肠癌的发病机制、预防和早期诊治结肠癌提供相关理论依据和实验基础。
研究结果:
雌激素信号传导通路相关基因中,ERβ及其靶基因PR启动子CpG岛在结肠癌细胞株HT-29、Lovo和Caco-2中均呈现为典型的异常高甲基化模式;原癌基因c-fos启动子CpG岛在三株结肠癌细胞中则表现为不完全性的部分甲基化。
RT-PCR检测结果显示,与内参基因相比,ERβmRNA在三株结肠癌细胞中均呈现为弱表达状况。细胞爬片的免疫组织化学检测结果显示,ERβ蛋白主要定位在胞核,胞浆也有少量表达,其中在Caco-2中呈现中低度表达状况,在Lovo和HT-29中则表现为弱表达。总的来说,无论是ERβmRNA还是ERβ蛋白在三株癌细胞株中的表达都是被抑制的。hMLH1基因mRNA在三株结肠癌细胞中的表达无显著差异,均表现为中度表达水平。Dnmt1、Dnmt3a、Dnmt3b和HMT在结肠癌细胞株中呈现不等的表达水平,Dnmt3a、Dnmt3b在分化良好的癌细胞中呈现过度表达状况,而在分化不良或未分化的癌细胞中则被抑制表达。
针对ERβ基因设计的特异性小干扰RNA片段(siRNA)作用于Caco-2后,ERβ基因mRNA表达显著下调;然而,Caco-2细胞中ERβ,PR和c-fos等基因启动子甲基化模式在RNAi前后却无任何改变;同时,对Dnmt1,Dnmt3a,Dnmt3b,HMT和hMLH1基因mRNA的检测也发现,RNAi作用前后这些基因的表达无显著改变。
终浓度分别为10-6mol/L、10-8mol/L的雌二醇(E2)分别作用于Caco-2细胞两周后,ERβ基因表达无明显增高或其他改变。提示,单纯应用E2作用癌细胞可能并不能诱导ERβ的表达。接下来的研究采用常规基因重组技术构建ERβ真核表达载体并导入结肠癌细胞Caco-2。结果表明,外源性ERβ基因的导入可以显著的激活雌激素信号传导通路基因(PR、c-fos)的表达(P<0.01),与此同时,该通路基因总体甲基化密度显著降低。结合甲基化酶谱(Dnmt1,Dnmt3a,Dnmt3b和HMT)表达水平的改变,我们推测,这种调控作用很可能是通过去甲基化机制来实现的。不过,因为并没有完全逆转原有的高甲基化模式,因此,ERβ对PR、c-fos的调控作用很可能是但又不完全是通过去甲基化机制来实现的。换句话说,结肠癌细胞中ERβ基因激活可以部分地逆转雌激素信号传导通路基因的甲基化模式,使PR基因(含经典的ERE元件)和c-fos原癌基因(含非经典的AP-1结合位点)发生部分去甲基化并恢复近似正常的表达,在此过程中ERβ基因本身也发生了去甲基化改变。此外,ERβ基因导入Caco-2后,hMLH1表达也明显降低。ERβ与hMLH1之间是否存在以及存在何种相关性,尚有待进一步研究。
我们成功的进行了SD新生大鼠结肠上皮细胞的体外原代培养,免疫组织化学检测表明,上皮细胞纯度达95%以上。我们针对ERβ基因设计合成的特异性甲基化寡核苷酸(MO)片段成功转染进入了结肠上皮细胞,并且在增殖比较旺盛的细胞团块中富集。MSP检测结果表明,转染进入细胞的MO片段成功诱导了ERβ基因启动子的特异性甲基化。结肠上皮细胞ERβ基因衰老性甲基化模型的建立,为从表观遗传学角度研究ERβ基因在结肠癌发生机制中的作用奠定了坚实的基础。
深入研究发现,ERβ基因发生衰老性甲基化而灭活的同时,下游的靶基因PR和c-fos的表达也显著降低。对表观遗传学酶谱的检测则表明,MO诱导前后从头甲基化酶(Dnmt3a,Dnmt3b)和组蛋白甲基化酶(HMT)的表达也发生了显著的改变,维持甲基化酶(Dnmt1)的表达却无明显变化。这表明,整个过程中发生了显著的酶促条件下的从无到有的基因高甲基化和组蛋白高甲基化等表观遗传学基因型改变。结合正常结肠上皮细胞中该通路非甲基化或低甲基化这一事实,就更容易理解上述改变。
研究结论:
我们的研究结果提示,在结肠上皮细胞中,除了经典的受体-配体结合方式外,ERβ基因还存在着表观遗传学作用方式和机制,作为结肠上皮细胞中的优势受体,ERβ基因的衰老性甲基化,对雌激素信号传导通路中相关基因启动子甲基化模式及正常的表达水平起着决定性作用:ERβ基因启动子衰老性甲基化→ERβ基因表达灭活→表遗传学酶谱活性发生改变,下游的PR,c-fos等基因启动子发生异常高甲基化→PR,c-fos等下游靶基因表达失活→正常的雌激素信号传导通路发生异常→结肠上皮细胞增殖异常,MSI和CIMP表型改变,最终促进癌变?我们的研究有助于探讨ERβ基因的衰老性甲基化现象在结直肠肿瘤发生过程中的意义,特别是对结肠上皮的表观遗传学影响,了解ERβ基因衰老性甲基化在结肠癌早期诊断、预防、预后评估以及治疗中的应用价值,我们的研究还有助于明确雌激素抑制结肠的肿瘤发生的作用机制,探索将此抑制作用用于已发生的肿瘤的治疗过程的应用价值和方法。
Objectives:
It is indicated that estrogen receptor (ER) gene may play an important role in the process of modifications of histone tails and nucleosome remodeling by recruiting transcription factors such as Histones acetyltransferases (HAT) and Histone methyltransferase(HMT),which suggests that ERβgene can also mediate epigenetic regulation on its downstream targeted genes and consequently participates in carcinogenesis except for the classical signaling pathway via estrogen reaction element(ERE).Then how does it perform this process in colon cancer?Since promoter hypermethylation could result in transcription inactivation and transcription inactivation could mediate epigenetic regulation on its downstream targeted genes,then is there a cause and effect relationship between promoter hypermethylation of ERβgene and its epigenetic regulation?In other words, Does whether aging hypermethylation of ERβpromoter trigger the epigenetic regulation on its downstream targeted genes or not? This research is just executed to try to answer these questions and to know about pathologic mechanism of ERβgene aging hypermethylation and further the pathogenesis of the female ascending colon caner.
Methods:
Promoter CpG islands methylation modes of ERβ, progesterone receptor (PR) and c-fos genes were determined by methylated specific PCR(MSP) and the mRNA levels of ERβ,DNA Methyltransferase(Dnmt) 1, Dnmt3a,Dnmt3b, Histone Methyltransferase(HMT) and hMLH1 genes were detected by RT-PCR in HT-29、Lovo and Caco-2 colon cancer cells,separately. The expression level of ERβgene was artificially down-regulated using small interfering RNA(siRNA) and up-regulated by treatment with estradiol or ERβeukaryotic expression vector,separately, to determine the modulating action on estrogen signaling by ERβgene and the possible mechanism in Caco-2 cells.For the first time, we have established a new functional primary culture cell model by inducement of ERβgene promoter aging hypermethylation in Sprague Dawley rat normal colonic epithelial cells using a novel methylated oligonucleotides(MOs).Suckling rat colonic epithelial cells were primary cultured in DMEM media. Two MOs complementary to promoter regions of ERβwere synthesized and used on the cultured cells to induce promoter hypermethylation of ERβgene.MSP method was used to determine the methylation status of ERβpromoter and RT-PCR was used to detect the expression abundances of ERβmRNA in the cultured cells after MOs treatment.To study the epigenetic regulation on downstream target genes by aging hypermethylation of ERβgene,the expression levels of PR,c-fos,hMLH1,and epigenetic enzymatic spectrum genes,such as Dnmt1,Dnmt3a,Dnmt3b and HMT,were detected by RT-PCR in the cell model 48hours after MOs treatment.
Results:
1.The ERβand PR genes promoter were hypermethylated in HT-29、Lovo and Caco-2 colon cancer cells(P<0.01), whereas the c-fos gene promoter which contained the AP-1 site, partly showed a methylated CpG islands in all the three cancer cells(P<0.05).
2.It was indicated that significant overexpression of Dnmt3b was seen in the human colon cancer cells while Dnmt1, HMT and hMLH1 genes were only modestly overexpressed.Dnmt3a and ERβgenes showed a very low expression level in all the three cancer cells. A significant discrimination of Dnmt3b mRNA expression levels was found between HT-29、Lovo and Caco-2 cells because Dnmt3b was present at high level in HT-29 and Lovo cell lines but declined drastically in Caco-2 cells.
3.siRNA targeted ERβgene in Caco-2 cells could not change promoter hypermethylation modes of ERβ,PR and c-fos genes as well as the expression levels of Dnmt1,Dnmt3a,Dnmt3b and HMT genes.It seemed to have no effect on estrogen signaling pathway by down-regulating ERβgene expression in Caco-2 cells.
4.Caco-2 cells were treated with 10-6mol/L or 10-8mol/L estradiol for 2 weeks to induce activation of ERβgene,but it failed.ERβeukaryotic expression vector was constructed successfully and then transfected into Caco-2 cells to reactivate ERβexpression. The mRNA levels of PR,c-fos,Dnmt3a and Dnmt3b gene were up-regulated in Caco-2 cells transfected with the recombinant compared with the control(P<0.01). The mRNA levels of Dnmt1,HMT and hMLH1 gene were down-regulated in Caco-2 cells transfected with the recombinant(P<0.01). At the same time,ERβ,PR and c-fos genes displayed an incomplete demethylating modifications in Caco-2 cells transfected with the recombinant.
5.Suckling rat colonic epithelium cells was successfully cultured in vitro.Identification by immunohistochemical staining showed that more than 95% of the cultured cells were epithelial. The methylated and unmethylated oligonucleotides(UMOs) we designed and synthesized were transfected into the colonic epithelium cells successfully and assembled in the nucleolus of cells which had a better proliferative activity.RT-PCR demonstrated that expression of ERβmRNA was significantly suppressed in the cells treated with MOs, whereas in the cells treated with UMOs as control was not.MSP analysis showed that ERβgene promoter in the cells treated with MOs was hypermethylated compared with control. 6.Further study indicated that expressions of downstream targeted genes of estrogen signaling pathway were repressed simultaneously when ERβmRNA was significantly suppressed in the cells treated with MOs.What’s more,the activity of epigenetic enzymatic spectrum genes(Dnmt1,Dnmt3a,Dnmt3b and HMT) has changed at the same time.
Conclusions:
The present results suggested that except for the classical signaling pathway via estrogen reaction element,aging hypermethylation of ERβgene promoter can also remarkably mediate epigenetic regulation on its downstream targeted genes and consequently result in turbulence of this signaling pathway,which may benefit the effort to seek for the pathogenesis of the female ascending colon caner.Transcriptional inactivation of ERβgene in colonic epithelium cells may be mediated by promoter hypermethylation of ERβgene.Aging hypermethylation of ERβand its modulation on downstream targeted genes may play a significant role in carcinogenesis in colon cancer.Detection of the abnormal hypermethylation mode of ERβgene promoter will contribute to early diagnosis and prognosis evaluation of the female ascending coloh cancer.
了解结肠癌细胞中雌激素信号传导通路(Estrogen Signaling)的异常甲基化模式以及其与转录失活的因果关系,探讨雌激素受体β亚型基因(ERβ)对雌激素信号传导通路的表观遗传学调控方式,从不同层次上深入研究ERβ基因衰老性甲基化的表观遗传学机制及其病理意义,了解ERβ基因甲基化在结肠癌早期诊断、预防、预后评估以及治疗中的应用价值,尤其是雌激素抑制结肠肿瘤发生的作用机制,探索将此抑制作用用于已发生的肿瘤的治疗过程的应用价值和方法。
研究方法:
在整个一系列实验过程中,作为预实验部分,我们首先采用甲基化特异性PCR(MSP)方法了解了结肠癌细胞株(HT-29,Caco-2和Lovo)中ERβ及其靶基因PR(含经典的ERE元件)和c-fos原癌基因(含非经典的AP-1结合位点)启动子CpG岛的甲基化模式,采用常规PCR方法检测了结肠癌细胞株中ERβ基因、hMLH1基因、DNA甲基化转移酶1(Dnmt1)、DNA甲基化转移酶3a(Dnmt3a)、DNA甲基化转移酶3b(Dnmt3b)以及组蛋白甲基化转移酶(HMT)等表观遗传学酶谱的表达水平,为后续的研究打下基础。
在此基础上,我们采用针对ERβ基因的RNAi技术体外抑制ERβ基因的表达,观察了ERβ基因转录失活对PR和c-fos基因启动子甲基化模式的调控以及表观遗传学酶谱表达的影响;同时,采用雌激素诱导或外源性ERβ基因导入等不同手段,正向调节ERβ基因表达,观察ERβ基因表达恢复或激活对雌激素信号传导通路靶基因启动子甲基化模式的调控以及表观遗传学酶谱表达的影响。通过对ERβ基因正反两个方向的表达调节,观察除了经典的受体-配体结合方式外,ERβ基因是否还存在表观遗传学调控方式或机制。
接下来的研究中,我们采用“甲基化特异性寡核苷酸技术”,设计并合成针对ERβ基因的特异性甲基化寡核苷酸片段,作用于原代培养的雌性乳鼠结肠上皮细胞中,以诱导ERβ基因启动子发生特异性甲基化而失活,从而体外构建ERβ基因衰老性甲基化的结肠上皮细胞模型,以期模拟或者还原ERβ基因在结肠癌细胞中的表型和基因型,并在此基础上观察ERβ基因衰老性甲基化对雌激素信号传导通路的表观遗传学调控效应,深入探讨ERβ基因衰老性甲基化的表观遗传学机制及其病理意义,尤其是在雌激素预防女性结肠癌发生中可能的作用机理,为研究结肠癌的发病机制、预防和早期诊治结肠癌提供相关理论依据和实验基础。
研究结果:
雌激素信号传导通路相关基因中,ERβ及其靶基因PR启动子CpG岛在结肠癌细胞株HT-29、Lovo和Caco-2中均呈现为典型的异常高甲基化模式;原癌基因c-fos启动子CpG岛在三株结肠癌细胞中则表现为不完全性的部分甲基化。
RT-PCR检测结果显示,与内参基因相比,ERβmRNA在三株结肠癌细胞中均呈现为弱表达状况。细胞爬片的免疫组织化学检测结果显示,ERβ蛋白主要定位在胞核,胞浆也有少量表达,其中在Caco-2中呈现中低度表达状况,在Lovo和HT-29中则表现为弱表达。总的来说,无论是ERβmRNA还是ERβ蛋白在三株癌细胞株中的表达都是被抑制的。hMLH1基因mRNA在三株结肠癌细胞中的表达无显著差异,均表现为中度表达水平。Dnmt1、Dnmt3a、Dnmt3b和HMT在结肠癌细胞株中呈现不等的表达水平,Dnmt3a、Dnmt3b在分化良好的癌细胞中呈现过度表达状况,而在分化不良或未分化的癌细胞中则被抑制表达。
针对ERβ基因设计的特异性小干扰RNA片段(siRNA)作用于Caco-2后,ERβ基因mRNA表达显著下调;然而,Caco-2细胞中ERβ,PR和c-fos等基因启动子甲基化模式在RNAi前后却无任何改变;同时,对Dnmt1,Dnmt3a,Dnmt3b,HMT和hMLH1基因mRNA的检测也发现,RNAi作用前后这些基因的表达无显著改变。
终浓度分别为10-6mol/L、10-8mol/L的雌二醇(E2)分别作用于Caco-2细胞两周后,ERβ基因表达无明显增高或其他改变。提示,单纯应用E2作用癌细胞可能并不能诱导ERβ的表达。接下来的研究采用常规基因重组技术构建ERβ真核表达载体并导入结肠癌细胞Caco-2。结果表明,外源性ERβ基因的导入可以显著的激活雌激素信号传导通路基因(PR、c-fos)的表达(P<0.01),与此同时,该通路基因总体甲基化密度显著降低。结合甲基化酶谱(Dnmt1,Dnmt3a,Dnmt3b和HMT)表达水平的改变,我们推测,这种调控作用很可能是通过去甲基化机制来实现的。不过,因为并没有完全逆转原有的高甲基化模式,因此,ERβ对PR、c-fos的调控作用很可能是但又不完全是通过去甲基化机制来实现的。换句话说,结肠癌细胞中ERβ基因激活可以部分地逆转雌激素信号传导通路基因的甲基化模式,使PR基因(含经典的ERE元件)和c-fos原癌基因(含非经典的AP-1结合位点)发生部分去甲基化并恢复近似正常的表达,在此过程中ERβ基因本身也发生了去甲基化改变。此外,ERβ基因导入Caco-2后,hMLH1表达也明显降低。ERβ与hMLH1之间是否存在以及存在何种相关性,尚有待进一步研究。
我们成功的进行了SD新生大鼠结肠上皮细胞的体外原代培养,免疫组织化学检测表明,上皮细胞纯度达95%以上。我们针对ERβ基因设计合成的特异性甲基化寡核苷酸(MO)片段成功转染进入了结肠上皮细胞,并且在增殖比较旺盛的细胞团块中富集。MSP检测结果表明,转染进入细胞的MO片段成功诱导了ERβ基因启动子的特异性甲基化。结肠上皮细胞ERβ基因衰老性甲基化模型的建立,为从表观遗传学角度研究ERβ基因在结肠癌发生机制中的作用奠定了坚实的基础。
深入研究发现,ERβ基因发生衰老性甲基化而灭活的同时,下游的靶基因PR和c-fos的表达也显著降低。对表观遗传学酶谱的检测则表明,MO诱导前后从头甲基化酶(Dnmt3a,Dnmt3b)和组蛋白甲基化酶(HMT)的表达也发生了显著的改变,维持甲基化酶(Dnmt1)的表达却无明显变化。这表明,整个过程中发生了显著的酶促条件下的从无到有的基因高甲基化和组蛋白高甲基化等表观遗传学基因型改变。结合正常结肠上皮细胞中该通路非甲基化或低甲基化这一事实,就更容易理解上述改变。
研究结论:
我们的研究结果提示,在结肠上皮细胞中,除了经典的受体-配体结合方式外,ERβ基因还存在着表观遗传学作用方式和机制,作为结肠上皮细胞中的优势受体,ERβ基因的衰老性甲基化,对雌激素信号传导通路中相关基因启动子甲基化模式及正常的表达水平起着决定性作用:ERβ基因启动子衰老性甲基化→ERβ基因表达灭活→表遗传学酶谱活性发生改变,下游的PR,c-fos等基因启动子发生异常高甲基化→PR,c-fos等下游靶基因表达失活→正常的雌激素信号传导通路发生异常→结肠上皮细胞增殖异常,MSI和CIMP表型改变,最终促进癌变?我们的研究有助于探讨ERβ基因的衰老性甲基化现象在结直肠肿瘤发生过程中的意义,特别是对结肠上皮的表观遗传学影响,了解ERβ基因衰老性甲基化在结肠癌早期诊断、预防、预后评估以及治疗中的应用价值,我们的研究还有助于明确雌激素抑制结肠的肿瘤发生的作用机制,探索将此抑制作用用于已发生的肿瘤的治疗过程的应用价值和方法。
Objectives:
It is indicated that estrogen receptor (ER) gene may play an important role in the process of modifications of histone tails and nucleosome remodeling by recruiting transcription factors such as Histones acetyltransferases (HAT) and Histone methyltransferase(HMT),which suggests that ERβgene can also mediate epigenetic regulation on its downstream targeted genes and consequently participates in carcinogenesis except for the classical signaling pathway via estrogen reaction element(ERE).Then how does it perform this process in colon cancer?Since promoter hypermethylation could result in transcription inactivation and transcription inactivation could mediate epigenetic regulation on its downstream targeted genes,then is there a cause and effect relationship between promoter hypermethylation of ERβgene and its epigenetic regulation?In other words, Does whether aging hypermethylation of ERβpromoter trigger the epigenetic regulation on its downstream targeted genes or not? This research is just executed to try to answer these questions and to know about pathologic mechanism of ERβgene aging hypermethylation and further the pathogenesis of the female ascending colon caner.
Methods:
Promoter CpG islands methylation modes of ERβ, progesterone receptor (PR) and c-fos genes were determined by methylated specific PCR(MSP) and the mRNA levels of ERβ,DNA Methyltransferase(Dnmt) 1, Dnmt3a,Dnmt3b, Histone Methyltransferase(HMT) and hMLH1 genes were detected by RT-PCR in HT-29、Lovo and Caco-2 colon cancer cells,separately. The expression level of ERβgene was artificially down-regulated using small interfering RNA(siRNA) and up-regulated by treatment with estradiol or ERβeukaryotic expression vector,separately, to determine the modulating action on estrogen signaling by ERβgene and the possible mechanism in Caco-2 cells.For the first time, we have established a new functional primary culture cell model by inducement of ERβgene promoter aging hypermethylation in Sprague Dawley rat normal colonic epithelial cells using a novel methylated oligonucleotides(MOs).Suckling rat colonic epithelial cells were primary cultured in DMEM media. Two MOs complementary to promoter regions of ERβwere synthesized and used on the cultured cells to induce promoter hypermethylation of ERβgene.MSP method was used to determine the methylation status of ERβpromoter and RT-PCR was used to detect the expression abundances of ERβmRNA in the cultured cells after MOs treatment.To study the epigenetic regulation on downstream target genes by aging hypermethylation of ERβgene,the expression levels of PR,c-fos,hMLH1,and epigenetic enzymatic spectrum genes,such as Dnmt1,Dnmt3a,Dnmt3b and HMT,were detected by RT-PCR in the cell model 48hours after MOs treatment.
Results:
1.The ERβand PR genes promoter were hypermethylated in HT-29、Lovo and Caco-2 colon cancer cells(P<0.01), whereas the c-fos gene promoter which contained the AP-1 site, partly showed a methylated CpG islands in all the three cancer cells(P<0.05).
2.It was indicated that significant overexpression of Dnmt3b was seen in the human colon cancer cells while Dnmt1, HMT and hMLH1 genes were only modestly overexpressed.Dnmt3a and ERβgenes showed a very low expression level in all the three cancer cells. A significant discrimination of Dnmt3b mRNA expression levels was found between HT-29、Lovo and Caco-2 cells because Dnmt3b was present at high level in HT-29 and Lovo cell lines but declined drastically in Caco-2 cells.
3.siRNA targeted ERβgene in Caco-2 cells could not change promoter hypermethylation modes of ERβ,PR and c-fos genes as well as the expression levels of Dnmt1,Dnmt3a,Dnmt3b and HMT genes.It seemed to have no effect on estrogen signaling pathway by down-regulating ERβgene expression in Caco-2 cells.
4.Caco-2 cells were treated with 10-6mol/L or 10-8mol/L estradiol for 2 weeks to induce activation of ERβgene,but it failed.ERβeukaryotic expression vector was constructed successfully and then transfected into Caco-2 cells to reactivate ERβexpression. The mRNA levels of PR,c-fos,Dnmt3a and Dnmt3b gene were up-regulated in Caco-2 cells transfected with the recombinant compared with the control(P<0.01). The mRNA levels of Dnmt1,HMT and hMLH1 gene were down-regulated in Caco-2 cells transfected with the recombinant(P<0.01). At the same time,ERβ,PR and c-fos genes displayed an incomplete demethylating modifications in Caco-2 cells transfected with the recombinant.
5.Suckling rat colonic epithelium cells was successfully cultured in vitro.Identification by immunohistochemical staining showed that more than 95% of the cultured cells were epithelial. The methylated and unmethylated oligonucleotides(UMOs) we designed and synthesized were transfected into the colonic epithelium cells successfully and assembled in the nucleolus of cells which had a better proliferative activity.RT-PCR demonstrated that expression of ERβmRNA was significantly suppressed in the cells treated with MOs, whereas in the cells treated with UMOs as control was not.MSP analysis showed that ERβgene promoter in the cells treated with MOs was hypermethylated compared with control. 6.Further study indicated that expressions of downstream targeted genes of estrogen signaling pathway were repressed simultaneously when ERβmRNA was significantly suppressed in the cells treated with MOs.What’s more,the activity of epigenetic enzymatic spectrum genes(Dnmt1,Dnmt3a,Dnmt3b and HMT) has changed at the same time.
Conclusions:
The present results suggested that except for the classical signaling pathway via estrogen reaction element,aging hypermethylation of ERβgene promoter can also remarkably mediate epigenetic regulation on its downstream targeted genes and consequently result in turbulence of this signaling pathway,which may benefit the effort to seek for the pathogenesis of the female ascending colon caner.Transcriptional inactivation of ERβgene in colonic epithelium cells may be mediated by promoter hypermethylation of ERβgene.Aging hypermethylation of ERβand its modulation on downstream targeted genes may play a significant role in carcinogenesis in colon cancer.Detection of the abnormal hypermethylation mode of ERβgene promoter will contribute to early diagnosis and prognosis evaluation of the female ascending coloh cancer.
引文
1 Grodstein F,Newcomb PA,Stampfer MJ. Postmenopausal hormone therapy and the risk of colorectal cancer :a review and meta-analysis. Am J Med,1999;106:574-582
2 Crandall CJ.Estrogen replacement therapy and colon cancer :a clinical review. J Women’s Healt h Gend Based Med,1999;8:1155-1166
3 Franceschi S, Gallus S, Talamini R,et al. Menopause and colorectal cancer. Br J Cancer,2000;82:1860-1862
4 Nanda K, Bastian LA, Hasselblad V, et al .Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis. Obstet Gynecol,1999;93:880-888
5 Takeyama J, Suzuki T, Inoue S,et al.Expression and cellular localization of estrogen receptors alpha and beta in the human fetus. J Clin Endocrinol Metab,2001;86:2258- 2262
6 Fiorelli G,Picariello L,Martineti V,et al.Functional estrogen receptorβin colon cancer cells.Biochem Biophys Res Commun,1999;26(2):521-527
7 Klinge CM. Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res,2001;29:2905-2919
8 Dardes RC,Jordan VC.Novel Agents to modulate oestrogen action. Br Med Bull, 2000;56 (3):773-786
9 Bardin A,Boulle N,Lazennec G,et al.Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocrine-Related Cancer,2004;11:537-551
10 Konstantinopoulos PA, Kominea A, Vandoros G,et al.Oestrogen receptor beta (ERbeta) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour's dedifferentiation. Eur J Cancer, 2003;39:1251-1258
11 Herman JG,Baylin SB.Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med,2003;349(21):2042-2054
12 Antequera F,Bird A.Number of CpG islands and genes in human and mouse.Proc Nail Acad Sci USA,1993;90(24):1995-1999
13 Cui H,Cruz Corren M,Giardiello FM,et al.Loss of IGF2 imprinting: a potential markerof colorectal cancer risk.Science,2003;299(5613):1753-1755
14 Baylin SB,Herman JG,Graff JR,et al.Alterntions in DNA methylation:a fundamental aspect of neoplasia. Adv Cancer Res,1998;72:141-196
15 TyckoB. Epigenetic gene silencing in cancer. J Clin Invest, 2000, 105(4): 401-407
16 Jones PA,Takai D.The role of DNA methylation in mammalian epigenetics.Science, 2001;293(5532):1068-1070
17 Lapidus RG,Nass SJ,Davidson NE.The loss of estrogen and progesterone receptor gene expression in human breast cancer. J Mammary Gland Biol Neoplasia,1998;3 (1):85-94
18 Lapidus RG,Nass SJ,Butash KA,et al.Mapping of ER gene CpG island methylation specific polymerase chain reaction. Cancer Res,1998;58(12):2515-2519
19 Zhao C,Lam EW,Sunters A,et al.Expression of estrogen receptor be ta isoforms in normal breast epithelial cells and breast cancer:regulationbymethylation. Oncogene, 2003;22(48):7600-7606
20 Altundag O, Altundag K, Gunduz M. DNA methylation inhibitor, procainamide, may decrease the tamoxifen resistance by inducing overexpression of the estrogen receptor beta in breast cancer patients. Med Hypotheses, 2004;63(4):684-687
21 Rody A,Holtrich U,Solbach C,et al.Methylation of estrogen receptor beta promoter correlates with loss of ER-beta expression in mammary carcinoma and is an early indication marker in premalignant lesions. Endocr Relat Cancer,2005;12(4):903-916
22 Zhu X, Leav I, Leung YK,et al.Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis. Am J Pathol,2004;164(6):2003-2012
23 Issa JPJ, Ottaviano YL, Celano P,et al. Methylation of the estrogen receptor CpG island links ageing and neoplasia in human colon. Nature Genet,1994;7:536–540
24 Wendy S, Post,Pascal J, et al. Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system. Cardiovascular Research, 1999;43(4):985-991
25 Métivier R,Penot G,Hübner MR,et al. Estrogen receptor-alpha directs ordered,cyclical, and combinatorial recruitment of cofactors on a natural target promoter.Cell,2003;115: 751-763
26 Leu YW,Yan PS,Fan M,et al.Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer. Cancer Res,2004;64:8184-8192
27 ingg JM,Jones PA.Genetic and epigenetic aspects of DNA methylation on genome expression,evolution,mutation and cacinogenesis. Cacinogenesis,1997;18:869-882
28 Yao X,Hu JF,Daniels M,et al.A methylated oligonucleotide inhibits IGF2 expression and enhances survival in a model of hepatocellular carcinoma. J Clin Invest, 2003;111: 265–273
1 Chung YG, Ratnam S, Chaillet JR,et al. Abnormal regulation of DNA methyltransferase expression in cloned mouse embryos. Biol Reprod.2003;69:146-153
2 Li E, Bestor TH, Jaenisch R. Targeted mutation of the DNA methyltransferase gene results in embryonic leathality. Cell.1992;69:915-926
3 Turek-Plewa J,Jagodziński PP.The role of mammalian DNA methyltransferases in the regulation of gene expression. Cell Mol Biol Lett .2005;10:631-647
4 Lapidus RG,Nass SJ,Davidson NE.The loss of estrogen and progesterone receptor gene expression in human breast cancer.J Mammary Gland BiolNeoplasia.1998;3:85-94
5 Takeyama J,Suzuki T, Inoue S, et al . Expression and cellular localization of estrogen receptorαandβin the human fetus.J Clin Endocrinol Metab.2001;86:2258-2262
6 Konstantinopoulos PA, Kominea A, Vandoros G,et al. Oestrogen receptor beta (ERbeta) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour's dedifferentiation. Eur J Cancer.2003; 39:1251-1258
7 Franceschi S,Gallus S,Talamini R,et al. Menopause and colorectal cancer. Br J Cancer.2000;82:1860-1862
8 Nanda K, Bastian LA, Hasselblad V,et al. Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis.Obstet Gynecol.1999;93:880-888
9 Klinge CM. Estrogen receptor interaction with estrogen response elements. NucleicAcids Res.2001;29 :2905-2919
10 Zhao C, Lam EW, Sunters A,et al.Expression of estrogen receptor beta isoforms in normal breast epithelial cells and breast cancer: regulation by methylation. Oncogene. 2003;22:7600-7606
11 Zhu X, Leav I, Leung YK. Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis. Am J Pathol.2004;164:2003-2012
12 Bardin A, Boulle N, Lazennec G,et al. Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocrine-Related Cancer.2004;11:537-551
13 Rody A, Holtrich U, Solbach C, et al.Methylation of estrogen receptor beta promoter correlates with loss of ER-beta expression in mammary carcinoma and is an early indication marker in premalignant lesions. Endocr Relat Cancer.2005;12:903-916
1 Herman JG,Baylin SB.Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med .2003;349:2042-2054
2 Cui H, Cruz-Correa M, Giardiello FM,et al.Loss of IGF2 imprinting:a potential marker of colorectal cancer risk.Science.2003;299:1753-1755
3 Jones PA,Takai D.The role of DNA methylation in mammalian epigenetics.Science. 2001;293:1068-1070
4 Luczak MW,Jagodzinski PP. The role of DNA methylation in cancer development. Folia Histochem Cytobiol.2006;44:143-154
5 Bestor TH.The DNA methyltransferases of mammals.Hum MolGenet.2000;9:2395- 2402
6 Schmidt WM, Sedivy R, Forstner B,et al. Progressive up-regulation of genes encoding DNA methyltransferases in the colorectal adenoma-carcinoma sequence. Mol Carcinog. 2007;46:766-772
7 Robertson KD,Uzvolgyi E,Liang G,et al.The human DNA methyltransferases (DNMTs)1, 3a and 3b:coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res.1999;27:2291-2298
8 Hermann A,Gowher H,Jeltsch A.Biochemistry and biology of mammalian DNA methyltransferases. Cell Mol Life Sci.2004;61:2571-2587
9 Robert M, Morin S, Beaulieu N,et al.DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat Genet.2003;33:61-65
10 Suzuki M,Sunaga N,Shames DS,et al.RNA interference-mediated knockdown of DNA methyltransferase 1 leads to promoter demethylation and gene re-expression in human lung and breast cancer cells. Cancer Res.2004;64:3137-3143
11 Karpf AR,Matsui S.Genetic disruption of cylosine DNA methyltransferase enzymes induces chromosomal instability in human cancer cells.Cancer Res.2005;65: 8635-8639
12 Zhu YM, Huang Q, Lin J, et al. Expression of human DNA methyltransferase 1 in colorectal cancer tissues and their corresponding distant normal tissues. Int J Colorectal Dis.2007;22:661-666
13 Etoh T, Kanai Y, Ushijima S, et al. Increased DNA methyltransferase 1 (DNMT1)protein expression correlates significantly with poorer tumor differentiation and frequent DNA hypermethylation of multiple CpG islands in gastric cancers. Am J Pathol.2004;164:689-699
14 Girault I, Tozlu S, Lidereau R,et al. Expression analysis of DNA methyltransferases 1,
3A, and 3B in sporadic breast carcinomas. Clin Cancer Res.2003;9:4415-4422
15 Eads CA, Danenberg KD, Kawakami K, et al. CpG island hypermethylation in hum an colorectal tumors is not associated with DNA methyltransferase overexpression. Cancer Res.1999;59:2302-2306
16 Oue N, Kuraoka K, Kuniyasu H,et al. DNA methylation status of hMLH1,p16(INK4a)and CDH1 is not associated with mRNA expression levels of DNA methyltransferase and DNA demethylase in gastric carcinomas. Oncol Rep.2001;8:1085-1089
17 Fatemi M, Hermann A, Gowher H, et al. Dnmt3a and Dnmt1 functionally cooperate during de novo methylation of DNA. Eur J Biochem.2002;269:4981-4984
18 Hsieh CL.The de novo methylation activity of Dnmt3a is distinctly different than that of Dnmt1. BMC Biochem.2005;6:6
19 Gowher H,Stockdale CJ,Goyal R,et al.De novo methylation of nucleosomal DNA by the mammalian Dnmt1 and Dnmt3A DNA Methyltransferases. Biochemistry. 2005;44:9899-9904
20 Araujo FD, Croteau S, Slack AD,et al. The DNMT1 target recognition domain resides in the N terminus. J Biol Chem.2001;276:6930-6936
21 Fatemi M, Hermann A, Pradhan S,et al. The activity of the murine DNA methyltransferase Dnmt1 is controlled by interaction of the catalytic domain with the N-terminal part of the enzyme leading to an allosteric activation of the enzyme after binding to methylated DNA. J Mol Biol .2001;309:1189-1199
22 Rhee I, Jair KW, Yen RW,et al. CpG methylation is maintained in human cancer cells lacking DNMT1. Nature.2000;404:1003-1007
23 Rhee I, Bachman KE, Park BH,et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells.Nature.2002;416:552-556
24 Leu YW,Rahmatpanah F,Shi H,et al.Double RNA interference of DNMT3b and DN MT1 enhances DNA demethylation and gene reactivation.Cancer Res.2003;63:6110- 6115
25 Ting AH, Jair KW, Suzuki H,et al. CpG island hypermethylation is maintained in human colorectal cancer cells after RNAi-mediated depletion of DNMT1. Nat Genet. 2004;36:582-584
26 Geiman TM, Sankpal UT, Robertson AK,et al . Isolation and characterization of a novel DNA methyltransferase complex linking DNMT3B with components of the mitotic chromosome condensation machinery. Nucleic Acids Res.2004;32:2716-2729
27 Kang MY, Lee BB, Kim YH,et al. Association of the SUV39H1 histone methyltransferase with the DNA methyltransferase 1 at mRNA expression level in primary colorectal cancer. Int J Cancer.2007;121:2192-2197
28 Li H, Rauch T, Chen ZX,et al. The histone methyltransferase SETDB1 and the DNA methyltransferase DNMT3A interact directly and localize to promoters silenced in cancer cells. J Biol Chem.2006;281:19489-19500
29 Espada J,Ballestar E,Fraga MF,et al.Human DNA methyltransferase 1 is required for maintenance of the histone H3 modification pattern.J Biol Chem.2004; 279:37175-37184
30 Takeyama J,Suzuki T, Inoue S, et al . Expression and cellular localization of estrogen receptorαandβin the human fetus.J Clin Endocrinol Metab.2001;86:2258-2262
31 Bardin A,Boulle N,Lazennec G,et al.Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocrine-Related Cancer.2004;11:537-551
32 Hsu HH, Cheng SF, Wu CC, et al.Apoptotic effects of over-expressed estrogen receptor beta on LoVo colon cancer cell is mediated by p53 signalings in a liganddependent manner. Chin J Physiol. 2006;49(2):110-116
33 Rody A, Holtrich U, Solbach C, et al.Methylation of estrogen receptor beta promoter correlates with loss of ER-beta expression in mammary carcinoma and is an early indication marker in premalignant lesions. Endocr Relat Cancer. 2005;12(4):903-916
34 Chang HG, Kim SJ, Chung KW, et al. Tamoxifen-resistant breast cancers show less frequent methylation of the estrogen receptor beta but not the estrogen receptor alpha gene. J Mol Med. 2005;83(2):132-139
35 Altundag O, Altundag K, Gunduz M. DNA methylation inhibitor, procainamide, may decrease the tamoxifen resistance by inducing overexpression of the estrogen receptor beta in breast cancer patients. Med Hypotheses. 2004;63(4):684-687
1 Leu YW, Yan PS, Fan M, et al. Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer. Cancer Res,2004;64:8184-8192
2 Takeyama J,Suzuki T,Inoue S,et al.Expression and cellular localization of estrogen receptors alpha and beta in the human fetus.J Clin Endocrinol Metab, 2001;86:2258- 2262
3 Fiorelli G,Picariello L,Martineti V,et al.Functional estrogen receptorβin colon cancer cells.Biochem Biophys Res Commun,1999;26(2):521-527
4 Grodstein F,Newcomb PA,Stampfer MJ.Postmenopausal hormone therapy and the risk of colorectal cancer :a review and meta-analysis. Am J Med,1999;106 :574-582
5 Crandall CJ.Estrogen replacement therapy and colon cancer:a clinical review. J Women’s Healt h Gend Based Med,1999;8:1155-1166
6 Franceschi S,Gallus S,Talamini R,et al. Menopause and colorectal cancer. Br J Cancer, 2000;82:1860-1862
7 Nanda K, Bastian LA, Hasselblad V,et alHormone replacement therapy and the risk of colorectal cancer: a meta-analysis.Obstet Gynecol,1999;93:880-888
8 Klinge CM. Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res,2001;29:2905-2919
9 Dardes RC,Jordan VC.Novel Agents to modulate oestrogen action.Br Med Bull, 2000;56 (3):773-786
10 Métivier R, Penot G, Hübner MR, et al. Estrogen receptorαdirects ordered,cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell,2003; 115:751-763
1 Grodstein F,Newcomb PA,Stampfer MJ.Postmenopausal hormone therapy and the risk of colorectal cancer :a review and meta-analysis. Am J Med,1999;106:574-582
2 Crandall CJ.Estrogen replacement therapy and colon cancer:a clinical review. J Women’s Healt h Gend Based Med,1999;8:1155-1166
3 Franceschi S,Gallus S,Talamini R,et al.Menopause and colorectal cancer.Br J Cancer,2000;82:1860-1862
4 Nanda K,Bastian LA,Hasselblad V, et al.Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis. Obstet Gynecol,1999;93:880-888
5 Takeyama J,Suzuki T,Inoue S,et al.Expression and cellular localization of estrogen receptors alpha and beta in the human fetus.J Clin Endocrinol Metab,2001;86:2258- 2262
6 Fiorelli G,Picariello L,Martineti V,et al.Functional estrogen receptorβin colon cancer cells.Biochem Biophys Res Commun,1999;26(2):521-527
7 Klinge CM. Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res,2001;29:2905-2919
8 Bardin A,Boulle N,Lazennec G,et al.Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocrine-Related Cancer,2004;11:537-551
9 Konstantinopoulos PA,Kominea A,Vandoros G,et al.Oestrogen receptor beta (ERbeta) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour's dedifferentiation. Eur J Cancer,2003;39:1251 -1258
10 Métivier R, Penot G, Hübner MR, et al. Estrogen receptorαdirects ordered,cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell,2003; 115:751-763
11 Leu YW,Yan PS,Fan M, et al.Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer. Cancer Res,2004;64:8184-8192
12 Wada-Hiraike O, Warner M, Gustafsson JA. New developments in oestrogen signaling in colonic epithelium. Biochem Soc Trans,2006;34:1114-1116
13 Wada-Hiraike O, Imamov O, Hiraike H,et al.Role of estrogen receptor beta in colonic epithelium.Proc Natl Acad Sci U S A ,2006;103:2959-2964
14 Campbell-Thompson M, Lynch IJ, Bhardwaj B. Expression of estrogen receptor (ER) subtypes and ERbeta isoforms in colon cancer. Cancer Res,2001;61:632-640
15 Xie LQ, Yu JP, Luo HS. Expression of estrogen receptor beta in human colorectal cancer.World J Gastroenterol,2004;10:214-217
16 Foley EF,Jazaeri AA,Shupnik MA,et al.Selective loss of estrogen receptor beta in malignant human colon. Cancer Res,2000;60:245-248
17 Leav I, Lau KM, Adams JY,et al. Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am J Pathol,2001;159:79-92
18 Zhao C, Lam EW, Sunters A,et al .Expression of estrogen receptor beta isoforms in normal breast epithelial cells and breast cancer: regulation by methylation. Oncogene, 2003;22:7600-7606
1 Herman JG,Baylin SB.Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med,2003;349(21):2042-2054
2 Antequera F,Bird A,Number of CpG islands and genes in human and mouse .Proc Nail Acad Sci USA,1993;90(24):1995-1999
3 Cui H,Cruz Corren M,Giardiello FM,et al.Loss of IGF2 imprinting: a potential marker of colorectal cancer risk.Science,2003;299(5613):1753-1755
4 Baylin SB,Herman JG,Graff JR,et al.Alterntions in DNA methylation : a fundamental aspect of neoplasia. Adv Cancer Res,1998;72:141-196
5 TyckoB. Epigenetic gene silencing in cancer. J Clin Invest, 2000;105(4): 401-407
6 Jones PA,Takai D.The role of DNA methylation in mammalian epigenetics.Science, 2001;293(5532):1068-1070
7 Lapidus RG,Nass SJ,Davidson NE. The loss of estrogen and progesterone receptor gene expression in human breast cancer.J Mammary Gland Biol Neoplasia,1998;3 (1):85-94.
8 Lapidus RG, Nass SJ, Butash KA, et al. Mapping of ER gene CpG island methylation specific polymerase chain reaction. Cancer Res,1998;58(12) :2515-2519
9 Zhao C,Lam EW,Sunters A, et al. Expression of estrogen receptor be ta isoforms in normal breast epithelial cells and breast cancer :regulationbymethylation.Oncogene,2003;22(48):7600-7606
10 Altundag O,Altundag K,Gunduz M. DNA methylation inhibitor, procainamide, may decrease the tamoxifen resistance by inducing overexpression of the estrogen receptor beta in breast cancer patients. Med Hypotheses,2004;63(4):684-687
11 Rody A,Holtrich U,Solbach C,et al. Methylation of estrogen receptor beta promoter correlates with loss of ER-beta expression in mammary carcinoma and is an early indication marker in premalignant lesions. Endocr Relat Cancer,2005;12(4):903-916
12 Zhu X,Leav I,Leung YK,et al.Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis. Am J Pathol,2004 ;164(6):2003-2012
13 Zingg JM,Jones PA.Genetic and epigenetic aspects of DNA methylation on genome expression,evolution,mutation and cacinogenesis. Cacinogenesis,1997;18:869-882
14 Yao X,Hu JF,Daniels M,et al.A methylated oligonucleotide inhibits IGF2 expression and enhances survival in a model of hepatocellular carcinoma. J Clin Invest, 2003;111: 265–273
15 Evans GS, Flint N, Somers AS,et al. The development of a method for the preparation of rat intestinal epithelial cell primary cultures.J Cell Sci,1992;101( Pt 1):219-231
16 Szyf M,Detich N.Regulation of the DNA methylation machinery and its role in cellular transformation. Prog Nucleic Acid Res Mol Biol, 2001;69:47-79
17 Issa JPJ,Ottaviano YL,Celano P,et al. Methylation of the estrogen receptor CpG island links ageing and neoplasia in human colon. Nature Genet,1994;7:536–540
18 Wendy S, Post,Pascal J, et al. Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system. Cardiovascular Research, 1999; 43:985–991
1 Métivier R,Penot G,Hübner MR,et al. Estrogen receptor-alpha directs ordered,cyclical, and combinatorial recruitment of cofactors on a natural target promoter.Cell.2003;115: 751-763
2 Leu YW,Yan PS,Fan M,et al.Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer. Cancer Res,2004;64:8184-8192
3 Klinge CM. Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res,2001;29:2905-2919
4 Dardes RC,Jordan VC. Novel Agents to modulate oestrogen action.Br Med Bull,2000; 56(3):773-786
5 Issa JPJ, Ottaviano YL, Celano P et al. Methylation of the estrogen receptor CpG island links ageing and neoplasia in human colon. Nature Genet,1994;7:536–540
6 Wendy S, Post,Pascal J, et al. Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system. Cardiovascular Research, 1999; 43:985–991
7 Grodstein F,Newcomb PA,Stampfer MJ.Postmenopausal hormone therapy and the risk of colorectal cancer:a review and meta-analysis. Am J Med,1999;106:574-582
8 Crandall CJ.Estrogen replacement therapy and colon cancer:a clinical review. JWomen’s Healt h Gend Based Med,1999;8:1155-1166
9 Franceschi S,Gallus S,Talamini R,et al.Menopause and colorectal cancer.Br J Cancer,2000;82:1860-1862
10 Nanda K,Bastian LA,Hasselblad V,et al.Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis. Obstet Gynecol,1999;93:880-888
11 Takeyama J,Suzuki T,Inoue S,et al.Expression and cellular localization of estrogen receptors alpha and beta in the human fetus . J Clin Endocrinol Metab,2001;86:2258- 2262
12 Fiorelli G,Picariello L,Martineti V,et al.Functional estrogen receptorβin colon cancer cells.Biochem Biophys Res Commun,1999;26(2):521-527
13 Lapidus RG,Nass SJ,Davidson NE.The loss of estrogen and progesterone receptor gene expression in human breast cancer. J Mammary Gland Biol Neoplasia,1998;3 (1):85-94
14 Lapidus RG,Nass SJ,Butash KA,et al.Mapping of ER gene CpG island methylation specific polymerase chain reaction. Cancer Res,1998;58(12):2515-2519
1 Kirk R,Capecchi MR.Site-directed mutagenesis by gene targeting in mouse embryoderived stem cells.Cell,1987;51:503-512
2 Gu H,Marth JD,Orban PC,et al.Deletion of a DNA polymerase beta gene segment in T cells using cell type-specific gene targeting.Science,1994;265(5168):103-106
3 Schmidt-Supprian M,Rajewsky K.Vagaries of conditional gene targeting. Nat Immunol,2007;8(7):665-668
4 Nolden L,Edenhofer F,Haupt S,et al. Site-specific recombination in human embryonic stem cells induced by cell-permeant Cre recombinase.Nat Methods,2006;3(6):461-467
5 Haupt S, Edenhofer F, Peitz M,et al Stage-specific conditional mutagenesis in mouse embryonic stem cell-derived neural cells and postmitotic neurons by direct delivery of biologically active Cre recombinase. Stem Cells,2007;25(1):181-188
6 Nathalie Dias, CA Stein. Antisense Oligonucleotides: Basic Concepts and Mechanisms. Molecular Cancer Therapeutics,2002;1:347-355
7 ScienceScope. Science ,1998;281 :625
8 Fire A,Xu S,Montgomery MK,et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans.Nature,1998;391 (6669) :806-811
9 McCaffrey AP,Meuse L,Pham TT,et al.Gene expression :RNA interference in adult mice. Nature,2002;418 (6893) :38-39
10 Lenz G. The RNA interference revolution.Braz J Med Biol Res,2005;38(12):1749- 1757
11 Novik KL,Nimmrich I,Genc B,et al. Epigenomics: genome-wide study of methylation phenomena. Curr Issues Mol Biol,2002;4(4):111-128
12 Jones PA,Takai D.The role of DNA methylation in mammalian epigenetics.Science, 2001;293(5532):1068-1070
13 Kiefer JC. Epigenetics in development. Dev Dyn,2007;236(4):1144-1156
14 Baylin SB,Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer,2006;6(2):107-116
15 Hatada I.Emerging technologies for genome-wide DNA methylation profiling in cancer. Crit Rev Oncog,2006;12(3-4):205-223
16 Esteller M. Dormant hypermethylated tumour suppressor genes: questions and answers. J Pathol,2005;205(2):172-180
17 Plass C,Smiraglia DJ.Genome-wide analysis of DNA methylation changes in human malignancies. Curr Top Microbiol Immunol,2006;310:179-198
18 Herman JG. Epigenetic changes in cancer and preneoplasia. Cold Spring Harb Symp Quant Biol,2005;70:329-333
19 Ballestar E, Esteller M. The impact of chromatin in human cancer: linking DNA methylation to gene silencing. Carcinogenesis,2002;23(7):1103–1109
20 Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet,2002;3(6):415–428
21 Nephew KP, Huang TH-M. Epigenetic gene silencing in cancer initiation and progression. Cancer Lett,2003;190(2):125–133
22 Baylin SB, Esteller M, Rountree MR, et al. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet,2001;10(7): 687–692
23 Rountree MR, Bachman KE, Herman JG, et al. DNA methylation, chromatin inheritance, and cancer. Oncogene,2001;20(24):3156–3165
24 Maeda G, Chiba T, Aoba T,et al. Epigenetic inactivation of E-cadherin by promoter hypermethylation in oral carcinoma cells. Odontology, 2007;95(1):24-29
25 Mueller W, Nutt CL, Ehrich M,et al. Downregulation of RUNX3 and TES by hypermethylation in glioblastoma. Oncogene, 2007;26(4):583-593
26 Ferres-Marco D,Gutierrez-Garcia I,Vallejo DM,et al.Epigenetic silencers and Notch collaborate to promote malignant tumours by Rb silencing. Nature,2006;439(7075): 430-436
27 Aguilera O, Fraga MF, Ballestar E,et al. Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer.Oncogene, 2006;25(29): 4116-4121
28 Zhu X, Leav I, Leung YK, et al. Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis. Am J Pathol. 2004,164(6):2003-2012
29 Szyf M,Detich N.Regulation of the DNA methylation machinery and its role incellular transformation. Prog Nucleic Acid Res Mol Biol,2001;69:47-79
30 Ogino S, Kawasaki T, Kirkner GJ,et al. 18q loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative (CIMP-0) and inversely with CIMP-low and CIMP-high.BMC Cancer,2007;7:72
31 Goel A,Nagasaka T,Arnold CN,et al.The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer.Gastro- enterology,2007;132(1):127-138
32 Ogino S, Kawasaki T, Ogawa A,et al.TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer.Hum Pathol, 2007;38(4):614-620
33 Kang S, Lee JM, Jeon ES,et al. RASSF1A hypermethylation and its inverse correlation with BRAF and/or KRAS mutations in MSI-associated endometrial carcinoma.Int J Cancer,2006;119(6):1316-1321
34 Noda H, Kato Y, Yoshikawa H,et al.Microsatellite instability caused by hMLH1 promoter methylation increases with tumor progression in right-sided sporadic colorectal cancer.Oncology,2005;69(4):354-362
35 Park HW, Kang HC, Kim IJ,et al.Correlation between hypermethylation of the RASSF2A promoter and K-ras/BRAF mutations in microsatellite-stable colorectal cancers.Int J Cancer,2007;120(1):7-12
36 Murrell A, Rakyan VK, Beck S. From genome to epigenome. Hum Mol Genet,2005; 14(1):R3-R10
37廖锦民.甲基化寡聚核苷酸作为靶基因抑制剂的研究进展.生命科学,1993;5(1):17-19
38熊克勇.用甲基化的寡聚核苷酸做反义制剂.生物工程进展,1992;12(1):15-19
39 Hashimoto S, Sakai M,Muramatsu M. 2'-O-methylated oligonucleotides in ribosomal
18S and 28S RNA of a mouse hepatoma, MH 134. Biochemistry,1975;14(9):1956- 1964
40于海文,吴泰璜,穆庆龄,等.HGF甲基化寡核苷酸对肝癌细胞系BEL-7402作用的研究.中国现代普通外科进展,2004;7(2):93-97
41李文欢,崔屹,朱菊人.甲基化寡核苷酸抑制MRP2表达逆转人肝癌细胞HepG2多药耐药的研究.癌症,2004;23(8):900-904
1汪建平,元云飞.结直肠癌DNA甲基化研究的现状.中华实验外科杂志,2004;21(10): 1279-1280
2陆嵘,房静远.表观遗传修饰与肿瘤.生命科学,2006;18(1):10-14
3 Bos JL,Fearon ER,Hamilton SR,et al.Prevalence of ras gene mutations in human colorectal cancers. Nature,1987;327(6120):293–297
4 Guan R J,Fu Y,Holt P R,et al.Association of K-ras mutations with p16 methylation in human coloncancer.Gastroenterology,1999;116(5):1063-1071
5 Van Engeland M,Roemen GM,Brink M,et al.K-ras mutations and RASSF1A promoter methylation in colorectal cancer. Oncogene,2002;21(23):3792-3795
6 Sikora K,Chan S,Evan G,et al. c-myc oncogene expression in colorectal cancer. Cancer,1987;59(7):1289-1295
7 Sharrard RM,Royds JA,Rogers S,et al.Patterns of methylation of the c-myc gene in human colorectal cancer progression. Br J Cancer,1992;65(5):667-672
8 Sardi I,Dal Canto M,Bartoletti R, et al.Abnormal c-myc oncogene DNA methylation in human bladder cancer:possible role in tumor progression.EurUrol,1997;31(2): 224-230
9 Roa JC,Roa I,Melo A,et al.p53 gene mutation in cancer of the colon and rectum. Rev Med Chil,2000;128(9):996-1004
10 Samowitz WS,Curtin K,Ma KN,et al. Prognostic significance of p53 mutations in colon cancer at the population level. Int J Cancer,2002;99(4):597-602
11 Paluszkiewicz P,Berbec H, Pawlowska-Wakowicz B,et al.p53 protein accumulation in colorectal cancer tissue has prognostic value only in left-sided colon tumours.Cancer Detect Prev,2004;28(4):252-259
12 Oshiro MM,Watts GS,Wozniak RJ,et al.Mutant p53 and aberrant cytosine methylation cooperate to silence gene expression. Oncogene,2003;22(23):3624-3634
13 Esteller M,Sparks A,Toyota M,et al.Analysis of asenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res,2000;60(16):4366-4371
14 Arnold CN,Goel A,Niedzwiecki D,et al.APC promoter hypermethylation contributes to the loss of APC expression in colorectal cancers with allelic loss on 5q. Cancer Biol Ther,2004;3(10):960-964
15 Guoren Deng,Geun-Am Song,Erik Pong,et al.Promoter Methylation Inhibits APC Gene Expression by Causing Changes in Chromatin Conformation and Interfering with the Binding of Transcription Factor CCAAT-Binding Factor.CancerResearch,2004; 64(8):2692-2698
16 Deng G, Song GA, Pong E, et al.Promoter Methylation Inhibits APC Gene Expression by Causing Changes in Chromatin Conformation and Interfering with the Binding of Transcription Factor CCAAT-Binding Factor. Cancer Res, 2004;64(8):2692-2698
17 Jie C,Christoph R,Cathy LD,et al.Molecular analysis of APC promoter methylation and protein expression in colorectal cancer metastasis. Carcinogenesis,2005;26(1): 37-43
18 Kim BN,Yamamoto H,Ikeda K,et al.Methylation and expression of p16INK4 tumorsuppressor gene in primary colorectal cancer tissues.Int J Oncol,2005;26(5): 1217-1226
19 Norrie MW,Hawkins NJ,Todd AV,et al.Inactivation of p16INK4a by CpG hypermehylation is not a frequent event in colorectal cancer. J Surg Oncol,2003; 84(3):143-150
20 Wagner KJ,Cooper WN,Grundy RG,et al.Frequent RASSF1A tumour suppressor gene promoter methylation in Wilms' tumour and colorectal cancer.Oncogene,2002;21(47): 7277-7282
21 Liu T,Tannergard P,Hackman P,et al.Missense mutations in hMLH1 associated with colorectal cancer. Hum Genet,1999;105(5):437-441
22 Kim JC,Kim HC,Roh SA,et al.hMLH1 and hMSH2 mutations in families with familial clustering of gastric cancer and hereditary non-polyposis colorectal cancer. Cancer Detect Prev,2001;25(6) :503-510
23 Noda H,Kato Y,Yoshikawa H,et al.Microsatellite instability caused by hMLH1 promoter methylation increases with tumor progression in right-sided sporadic colorectal cancer.Oncology,2005;69(4):354-362
24 Fiorelli G,Picariello L,Martineti V,et al. Functional estrogen receptor beta in colon cancer cells. Biochem Biophys Res Commun,1999;261(2):521-527
25 Hsu HH,Cheng SF,Wu CC,et al.Apoptotic effects of over-expressed estrogen receptor-beta on LoVo colon cancer cell is mediated by p53 signalings in a ligand-dependent manner. Chin J Physiol,2006;49(2):110-116
26 Rody A,Holtrich U,Solbach C,et al.Methylation of estrogen receptor beta promoter correlates with loss of ER-beta expression in mammary carcinoma and is an early indication marker in premalignant lesions. Endocr Relat Cancer,2005;12(4):903-916
27 Altundag O,Altundag K,Gunduz M.DNA methylation inhibitor, procainamide, may decrease the tamoxifen resistance by inducing overexpression of the estrogen receptor beta in breast cancer patients. Med Hypotheses,2004;63(4):684-687
2 Crandall CJ.Estrogen replacement therapy and colon cancer :a clinical review. J Women’s Healt h Gend Based Med,1999;8:1155-1166
3 Franceschi S, Gallus S, Talamini R,et al. Menopause and colorectal cancer. Br J Cancer,2000;82:1860-1862
4 Nanda K, Bastian LA, Hasselblad V, et al .Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis. Obstet Gynecol,1999;93:880-888
5 Takeyama J, Suzuki T, Inoue S,et al.Expression and cellular localization of estrogen receptors alpha and beta in the human fetus. J Clin Endocrinol Metab,2001;86:2258- 2262
6 Fiorelli G,Picariello L,Martineti V,et al.Functional estrogen receptorβin colon cancer cells.Biochem Biophys Res Commun,1999;26(2):521-527
7 Klinge CM. Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res,2001;29:2905-2919
8 Dardes RC,Jordan VC.Novel Agents to modulate oestrogen action. Br Med Bull, 2000;56 (3):773-786
9 Bardin A,Boulle N,Lazennec G,et al.Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocrine-Related Cancer,2004;11:537-551
10 Konstantinopoulos PA, Kominea A, Vandoros G,et al.Oestrogen receptor beta (ERbeta) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour's dedifferentiation. Eur J Cancer, 2003;39:1251-1258
11 Herman JG,Baylin SB.Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med,2003;349(21):2042-2054
12 Antequera F,Bird A.Number of CpG islands and genes in human and mouse.Proc Nail Acad Sci USA,1993;90(24):1995-1999
13 Cui H,Cruz Corren M,Giardiello FM,et al.Loss of IGF2 imprinting: a potential markerof colorectal cancer risk.Science,2003;299(5613):1753-1755
14 Baylin SB,Herman JG,Graff JR,et al.Alterntions in DNA methylation:a fundamental aspect of neoplasia. Adv Cancer Res,1998;72:141-196
15 TyckoB. Epigenetic gene silencing in cancer. J Clin Invest, 2000, 105(4): 401-407
16 Jones PA,Takai D.The role of DNA methylation in mammalian epigenetics.Science, 2001;293(5532):1068-1070
17 Lapidus RG,Nass SJ,Davidson NE.The loss of estrogen and progesterone receptor gene expression in human breast cancer. J Mammary Gland Biol Neoplasia,1998;3 (1):85-94
18 Lapidus RG,Nass SJ,Butash KA,et al.Mapping of ER gene CpG island methylation specific polymerase chain reaction. Cancer Res,1998;58(12):2515-2519
19 Zhao C,Lam EW,Sunters A,et al.Expression of estrogen receptor be ta isoforms in normal breast epithelial cells and breast cancer:regulationbymethylation. Oncogene, 2003;22(48):7600-7606
20 Altundag O, Altundag K, Gunduz M. DNA methylation inhibitor, procainamide, may decrease the tamoxifen resistance by inducing overexpression of the estrogen receptor beta in breast cancer patients. Med Hypotheses, 2004;63(4):684-687
21 Rody A,Holtrich U,Solbach C,et al.Methylation of estrogen receptor beta promoter correlates with loss of ER-beta expression in mammary carcinoma and is an early indication marker in premalignant lesions. Endocr Relat Cancer,2005;12(4):903-916
22 Zhu X, Leav I, Leung YK,et al.Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis. Am J Pathol,2004;164(6):2003-2012
23 Issa JPJ, Ottaviano YL, Celano P,et al. Methylation of the estrogen receptor CpG island links ageing and neoplasia in human colon. Nature Genet,1994;7:536–540
24 Wendy S, Post,Pascal J, et al. Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system. Cardiovascular Research, 1999;43(4):985-991
25 Métivier R,Penot G,Hübner MR,et al. Estrogen receptor-alpha directs ordered,cyclical, and combinatorial recruitment of cofactors on a natural target promoter.Cell,2003;115: 751-763
26 Leu YW,Yan PS,Fan M,et al.Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer. Cancer Res,2004;64:8184-8192
27 ingg JM,Jones PA.Genetic and epigenetic aspects of DNA methylation on genome expression,evolution,mutation and cacinogenesis. Cacinogenesis,1997;18:869-882
28 Yao X,Hu JF,Daniels M,et al.A methylated oligonucleotide inhibits IGF2 expression and enhances survival in a model of hepatocellular carcinoma. J Clin Invest, 2003;111: 265–273
1 Chung YG, Ratnam S, Chaillet JR,et al. Abnormal regulation of DNA methyltransferase expression in cloned mouse embryos. Biol Reprod.2003;69:146-153
2 Li E, Bestor TH, Jaenisch R. Targeted mutation of the DNA methyltransferase gene results in embryonic leathality. Cell.1992;69:915-926
3 Turek-Plewa J,Jagodziński PP.The role of mammalian DNA methyltransferases in the regulation of gene expression. Cell Mol Biol Lett .2005;10:631-647
4 Lapidus RG,Nass SJ,Davidson NE.The loss of estrogen and progesterone receptor gene expression in human breast cancer.J Mammary Gland BiolNeoplasia.1998;3:85-94
5 Takeyama J,Suzuki T, Inoue S, et al . Expression and cellular localization of estrogen receptorαandβin the human fetus.J Clin Endocrinol Metab.2001;86:2258-2262
6 Konstantinopoulos PA, Kominea A, Vandoros G,et al. Oestrogen receptor beta (ERbeta) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour's dedifferentiation. Eur J Cancer.2003; 39:1251-1258
7 Franceschi S,Gallus S,Talamini R,et al. Menopause and colorectal cancer. Br J Cancer.2000;82:1860-1862
8 Nanda K, Bastian LA, Hasselblad V,et al. Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis.Obstet Gynecol.1999;93:880-888
9 Klinge CM. Estrogen receptor interaction with estrogen response elements. NucleicAcids Res.2001;29 :2905-2919
10 Zhao C, Lam EW, Sunters A,et al.Expression of estrogen receptor beta isoforms in normal breast epithelial cells and breast cancer: regulation by methylation. Oncogene. 2003;22:7600-7606
11 Zhu X, Leav I, Leung YK. Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis. Am J Pathol.2004;164:2003-2012
12 Bardin A, Boulle N, Lazennec G,et al. Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocrine-Related Cancer.2004;11:537-551
13 Rody A, Holtrich U, Solbach C, et al.Methylation of estrogen receptor beta promoter correlates with loss of ER-beta expression in mammary carcinoma and is an early indication marker in premalignant lesions. Endocr Relat Cancer.2005;12:903-916
1 Herman JG,Baylin SB.Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med .2003;349:2042-2054
2 Cui H, Cruz-Correa M, Giardiello FM,et al.Loss of IGF2 imprinting:a potential marker of colorectal cancer risk.Science.2003;299:1753-1755
3 Jones PA,Takai D.The role of DNA methylation in mammalian epigenetics.Science. 2001;293:1068-1070
4 Luczak MW,Jagodzinski PP. The role of DNA methylation in cancer development. Folia Histochem Cytobiol.2006;44:143-154
5 Bestor TH.The DNA methyltransferases of mammals.Hum MolGenet.2000;9:2395- 2402
6 Schmidt WM, Sedivy R, Forstner B,et al. Progressive up-regulation of genes encoding DNA methyltransferases in the colorectal adenoma-carcinoma sequence. Mol Carcinog. 2007;46:766-772
7 Robertson KD,Uzvolgyi E,Liang G,et al.The human DNA methyltransferases (DNMTs)1, 3a and 3b:coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res.1999;27:2291-2298
8 Hermann A,Gowher H,Jeltsch A.Biochemistry and biology of mammalian DNA methyltransferases. Cell Mol Life Sci.2004;61:2571-2587
9 Robert M, Morin S, Beaulieu N,et al.DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat Genet.2003;33:61-65
10 Suzuki M,Sunaga N,Shames DS,et al.RNA interference-mediated knockdown of DNA methyltransferase 1 leads to promoter demethylation and gene re-expression in human lung and breast cancer cells. Cancer Res.2004;64:3137-3143
11 Karpf AR,Matsui S.Genetic disruption of cylosine DNA methyltransferase enzymes induces chromosomal instability in human cancer cells.Cancer Res.2005;65: 8635-8639
12 Zhu YM, Huang Q, Lin J, et al. Expression of human DNA methyltransferase 1 in colorectal cancer tissues and their corresponding distant normal tissues. Int J Colorectal Dis.2007;22:661-666
13 Etoh T, Kanai Y, Ushijima S, et al. Increased DNA methyltransferase 1 (DNMT1)protein expression correlates significantly with poorer tumor differentiation and frequent DNA hypermethylation of multiple CpG islands in gastric cancers. Am J Pathol.2004;164:689-699
14 Girault I, Tozlu S, Lidereau R,et al. Expression analysis of DNA methyltransferases 1,
3A, and 3B in sporadic breast carcinomas. Clin Cancer Res.2003;9:4415-4422
15 Eads CA, Danenberg KD, Kawakami K, et al. CpG island hypermethylation in hum an colorectal tumors is not associated with DNA methyltransferase overexpression. Cancer Res.1999;59:2302-2306
16 Oue N, Kuraoka K, Kuniyasu H,et al. DNA methylation status of hMLH1,p16(INK4a)and CDH1 is not associated with mRNA expression levels of DNA methyltransferase and DNA demethylase in gastric carcinomas. Oncol Rep.2001;8:1085-1089
17 Fatemi M, Hermann A, Gowher H, et al. Dnmt3a and Dnmt1 functionally cooperate during de novo methylation of DNA. Eur J Biochem.2002;269:4981-4984
18 Hsieh CL.The de novo methylation activity of Dnmt3a is distinctly different than that of Dnmt1. BMC Biochem.2005;6:6
19 Gowher H,Stockdale CJ,Goyal R,et al.De novo methylation of nucleosomal DNA by the mammalian Dnmt1 and Dnmt3A DNA Methyltransferases. Biochemistry. 2005;44:9899-9904
20 Araujo FD, Croteau S, Slack AD,et al. The DNMT1 target recognition domain resides in the N terminus. J Biol Chem.2001;276:6930-6936
21 Fatemi M, Hermann A, Pradhan S,et al. The activity of the murine DNA methyltransferase Dnmt1 is controlled by interaction of the catalytic domain with the N-terminal part of the enzyme leading to an allosteric activation of the enzyme after binding to methylated DNA. J Mol Biol .2001;309:1189-1199
22 Rhee I, Jair KW, Yen RW,et al. CpG methylation is maintained in human cancer cells lacking DNMT1. Nature.2000;404:1003-1007
23 Rhee I, Bachman KE, Park BH,et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells.Nature.2002;416:552-556
24 Leu YW,Rahmatpanah F,Shi H,et al.Double RNA interference of DNMT3b and DN MT1 enhances DNA demethylation and gene reactivation.Cancer Res.2003;63:6110- 6115
25 Ting AH, Jair KW, Suzuki H,et al. CpG island hypermethylation is maintained in human colorectal cancer cells after RNAi-mediated depletion of DNMT1. Nat Genet. 2004;36:582-584
26 Geiman TM, Sankpal UT, Robertson AK,et al . Isolation and characterization of a novel DNA methyltransferase complex linking DNMT3B with components of the mitotic chromosome condensation machinery. Nucleic Acids Res.2004;32:2716-2729
27 Kang MY, Lee BB, Kim YH,et al. Association of the SUV39H1 histone methyltransferase with the DNA methyltransferase 1 at mRNA expression level in primary colorectal cancer. Int J Cancer.2007;121:2192-2197
28 Li H, Rauch T, Chen ZX,et al. The histone methyltransferase SETDB1 and the DNA methyltransferase DNMT3A interact directly and localize to promoters silenced in cancer cells. J Biol Chem.2006;281:19489-19500
29 Espada J,Ballestar E,Fraga MF,et al.Human DNA methyltransferase 1 is required for maintenance of the histone H3 modification pattern.J Biol Chem.2004; 279:37175-37184
30 Takeyama J,Suzuki T, Inoue S, et al . Expression and cellular localization of estrogen receptorαandβin the human fetus.J Clin Endocrinol Metab.2001;86:2258-2262
31 Bardin A,Boulle N,Lazennec G,et al.Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocrine-Related Cancer.2004;11:537-551
32 Hsu HH, Cheng SF, Wu CC, et al.Apoptotic effects of over-expressed estrogen receptor beta on LoVo colon cancer cell is mediated by p53 signalings in a liganddependent manner. Chin J Physiol. 2006;49(2):110-116
33 Rody A, Holtrich U, Solbach C, et al.Methylation of estrogen receptor beta promoter correlates with loss of ER-beta expression in mammary carcinoma and is an early indication marker in premalignant lesions. Endocr Relat Cancer. 2005;12(4):903-916
34 Chang HG, Kim SJ, Chung KW, et al. Tamoxifen-resistant breast cancers show less frequent methylation of the estrogen receptor beta but not the estrogen receptor alpha gene. J Mol Med. 2005;83(2):132-139
35 Altundag O, Altundag K, Gunduz M. DNA methylation inhibitor, procainamide, may decrease the tamoxifen resistance by inducing overexpression of the estrogen receptor beta in breast cancer patients. Med Hypotheses. 2004;63(4):684-687
1 Leu YW, Yan PS, Fan M, et al. Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer. Cancer Res,2004;64:8184-8192
2 Takeyama J,Suzuki T,Inoue S,et al.Expression and cellular localization of estrogen receptors alpha and beta in the human fetus.J Clin Endocrinol Metab, 2001;86:2258- 2262
3 Fiorelli G,Picariello L,Martineti V,et al.Functional estrogen receptorβin colon cancer cells.Biochem Biophys Res Commun,1999;26(2):521-527
4 Grodstein F,Newcomb PA,Stampfer MJ.Postmenopausal hormone therapy and the risk of colorectal cancer :a review and meta-analysis. Am J Med,1999;106 :574-582
5 Crandall CJ.Estrogen replacement therapy and colon cancer:a clinical review. J Women’s Healt h Gend Based Med,1999;8:1155-1166
6 Franceschi S,Gallus S,Talamini R,et al. Menopause and colorectal cancer. Br J Cancer, 2000;82:1860-1862
7 Nanda K, Bastian LA, Hasselblad V,et alHormone replacement therapy and the risk of colorectal cancer: a meta-analysis.Obstet Gynecol,1999;93:880-888
8 Klinge CM. Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res,2001;29:2905-2919
9 Dardes RC,Jordan VC.Novel Agents to modulate oestrogen action.Br Med Bull, 2000;56 (3):773-786
10 Métivier R, Penot G, Hübner MR, et al. Estrogen receptorαdirects ordered,cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell,2003; 115:751-763
1 Grodstein F,Newcomb PA,Stampfer MJ.Postmenopausal hormone therapy and the risk of colorectal cancer :a review and meta-analysis. Am J Med,1999;106:574-582
2 Crandall CJ.Estrogen replacement therapy and colon cancer:a clinical review. J Women’s Healt h Gend Based Med,1999;8:1155-1166
3 Franceschi S,Gallus S,Talamini R,et al.Menopause and colorectal cancer.Br J Cancer,2000;82:1860-1862
4 Nanda K,Bastian LA,Hasselblad V, et al.Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis. Obstet Gynecol,1999;93:880-888
5 Takeyama J,Suzuki T,Inoue S,et al.Expression and cellular localization of estrogen receptors alpha and beta in the human fetus.J Clin Endocrinol Metab,2001;86:2258- 2262
6 Fiorelli G,Picariello L,Martineti V,et al.Functional estrogen receptorβin colon cancer cells.Biochem Biophys Res Commun,1999;26(2):521-527
7 Klinge CM. Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res,2001;29:2905-2919
8 Bardin A,Boulle N,Lazennec G,et al.Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocrine-Related Cancer,2004;11:537-551
9 Konstantinopoulos PA,Kominea A,Vandoros G,et al.Oestrogen receptor beta (ERbeta) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour's dedifferentiation. Eur J Cancer,2003;39:1251 -1258
10 Métivier R, Penot G, Hübner MR, et al. Estrogen receptorαdirects ordered,cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell,2003; 115:751-763
11 Leu YW,Yan PS,Fan M, et al.Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer. Cancer Res,2004;64:8184-8192
12 Wada-Hiraike O, Warner M, Gustafsson JA. New developments in oestrogen signaling in colonic epithelium. Biochem Soc Trans,2006;34:1114-1116
13 Wada-Hiraike O, Imamov O, Hiraike H,et al.Role of estrogen receptor beta in colonic epithelium.Proc Natl Acad Sci U S A ,2006;103:2959-2964
14 Campbell-Thompson M, Lynch IJ, Bhardwaj B. Expression of estrogen receptor (ER) subtypes and ERbeta isoforms in colon cancer. Cancer Res,2001;61:632-640
15 Xie LQ, Yu JP, Luo HS. Expression of estrogen receptor beta in human colorectal cancer.World J Gastroenterol,2004;10:214-217
16 Foley EF,Jazaeri AA,Shupnik MA,et al.Selective loss of estrogen receptor beta in malignant human colon. Cancer Res,2000;60:245-248
17 Leav I, Lau KM, Adams JY,et al. Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am J Pathol,2001;159:79-92
18 Zhao C, Lam EW, Sunters A,et al .Expression of estrogen receptor beta isoforms in normal breast epithelial cells and breast cancer: regulation by methylation. Oncogene, 2003;22:7600-7606
1 Herman JG,Baylin SB.Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med,2003;349(21):2042-2054
2 Antequera F,Bird A,Number of CpG islands and genes in human and mouse .Proc Nail Acad Sci USA,1993;90(24):1995-1999
3 Cui H,Cruz Corren M,Giardiello FM,et al.Loss of IGF2 imprinting: a potential marker of colorectal cancer risk.Science,2003;299(5613):1753-1755
4 Baylin SB,Herman JG,Graff JR,et al.Alterntions in DNA methylation : a fundamental aspect of neoplasia. Adv Cancer Res,1998;72:141-196
5 TyckoB. Epigenetic gene silencing in cancer. J Clin Invest, 2000;105(4): 401-407
6 Jones PA,Takai D.The role of DNA methylation in mammalian epigenetics.Science, 2001;293(5532):1068-1070
7 Lapidus RG,Nass SJ,Davidson NE. The loss of estrogen and progesterone receptor gene expression in human breast cancer.J Mammary Gland Biol Neoplasia,1998;3 (1):85-94.
8 Lapidus RG, Nass SJ, Butash KA, et al. Mapping of ER gene CpG island methylation specific polymerase chain reaction. Cancer Res,1998;58(12) :2515-2519
9 Zhao C,Lam EW,Sunters A, et al. Expression of estrogen receptor be ta isoforms in normal breast epithelial cells and breast cancer :regulationbymethylation.Oncogene,2003;22(48):7600-7606
10 Altundag O,Altundag K,Gunduz M. DNA methylation inhibitor, procainamide, may decrease the tamoxifen resistance by inducing overexpression of the estrogen receptor beta in breast cancer patients. Med Hypotheses,2004;63(4):684-687
11 Rody A,Holtrich U,Solbach C,et al. Methylation of estrogen receptor beta promoter correlates with loss of ER-beta expression in mammary carcinoma and is an early indication marker in premalignant lesions. Endocr Relat Cancer,2005;12(4):903-916
12 Zhu X,Leav I,Leung YK,et al.Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis. Am J Pathol,2004 ;164(6):2003-2012
13 Zingg JM,Jones PA.Genetic and epigenetic aspects of DNA methylation on genome expression,evolution,mutation and cacinogenesis. Cacinogenesis,1997;18:869-882
14 Yao X,Hu JF,Daniels M,et al.A methylated oligonucleotide inhibits IGF2 expression and enhances survival in a model of hepatocellular carcinoma. J Clin Invest, 2003;111: 265–273
15 Evans GS, Flint N, Somers AS,et al. The development of a method for the preparation of rat intestinal epithelial cell primary cultures.J Cell Sci,1992;101( Pt 1):219-231
16 Szyf M,Detich N.Regulation of the DNA methylation machinery and its role in cellular transformation. Prog Nucleic Acid Res Mol Biol, 2001;69:47-79
17 Issa JPJ,Ottaviano YL,Celano P,et al. Methylation of the estrogen receptor CpG island links ageing and neoplasia in human colon. Nature Genet,1994;7:536–540
18 Wendy S, Post,Pascal J, et al. Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system. Cardiovascular Research, 1999; 43:985–991
1 Métivier R,Penot G,Hübner MR,et al. Estrogen receptor-alpha directs ordered,cyclical, and combinatorial recruitment of cofactors on a natural target promoter.Cell.2003;115: 751-763
2 Leu YW,Yan PS,Fan M,et al.Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer. Cancer Res,2004;64:8184-8192
3 Klinge CM. Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res,2001;29:2905-2919
4 Dardes RC,Jordan VC. Novel Agents to modulate oestrogen action.Br Med Bull,2000; 56(3):773-786
5 Issa JPJ, Ottaviano YL, Celano P et al. Methylation of the estrogen receptor CpG island links ageing and neoplasia in human colon. Nature Genet,1994;7:536–540
6 Wendy S, Post,Pascal J, et al. Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system. Cardiovascular Research, 1999; 43:985–991
7 Grodstein F,Newcomb PA,Stampfer MJ.Postmenopausal hormone therapy and the risk of colorectal cancer:a review and meta-analysis. Am J Med,1999;106:574-582
8 Crandall CJ.Estrogen replacement therapy and colon cancer:a clinical review. JWomen’s Healt h Gend Based Med,1999;8:1155-1166
9 Franceschi S,Gallus S,Talamini R,et al.Menopause and colorectal cancer.Br J Cancer,2000;82:1860-1862
10 Nanda K,Bastian LA,Hasselblad V,et al.Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis. Obstet Gynecol,1999;93:880-888
11 Takeyama J,Suzuki T,Inoue S,et al.Expression and cellular localization of estrogen receptors alpha and beta in the human fetus . J Clin Endocrinol Metab,2001;86:2258- 2262
12 Fiorelli G,Picariello L,Martineti V,et al.Functional estrogen receptorβin colon cancer cells.Biochem Biophys Res Commun,1999;26(2):521-527
13 Lapidus RG,Nass SJ,Davidson NE.The loss of estrogen and progesterone receptor gene expression in human breast cancer. J Mammary Gland Biol Neoplasia,1998;3 (1):85-94
14 Lapidus RG,Nass SJ,Butash KA,et al.Mapping of ER gene CpG island methylation specific polymerase chain reaction. Cancer Res,1998;58(12):2515-2519
1 Kirk R,Capecchi MR.Site-directed mutagenesis by gene targeting in mouse embryoderived stem cells.Cell,1987;51:503-512
2 Gu H,Marth JD,Orban PC,et al.Deletion of a DNA polymerase beta gene segment in T cells using cell type-specific gene targeting.Science,1994;265(5168):103-106
3 Schmidt-Supprian M,Rajewsky K.Vagaries of conditional gene targeting. Nat Immunol,2007;8(7):665-668
4 Nolden L,Edenhofer F,Haupt S,et al. Site-specific recombination in human embryonic stem cells induced by cell-permeant Cre recombinase.Nat Methods,2006;3(6):461-467
5 Haupt S, Edenhofer F, Peitz M,et al Stage-specific conditional mutagenesis in mouse embryonic stem cell-derived neural cells and postmitotic neurons by direct delivery of biologically active Cre recombinase. Stem Cells,2007;25(1):181-188
6 Nathalie Dias, CA Stein. Antisense Oligonucleotides: Basic Concepts and Mechanisms. Molecular Cancer Therapeutics,2002;1:347-355
7 ScienceScope. Science ,1998;281 :625
8 Fire A,Xu S,Montgomery MK,et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans.Nature,1998;391 (6669) :806-811
9 McCaffrey AP,Meuse L,Pham TT,et al.Gene expression :RNA interference in adult mice. Nature,2002;418 (6893) :38-39
10 Lenz G. The RNA interference revolution.Braz J Med Biol Res,2005;38(12):1749- 1757
11 Novik KL,Nimmrich I,Genc B,et al. Epigenomics: genome-wide study of methylation phenomena. Curr Issues Mol Biol,2002;4(4):111-128
12 Jones PA,Takai D.The role of DNA methylation in mammalian epigenetics.Science, 2001;293(5532):1068-1070
13 Kiefer JC. Epigenetics in development. Dev Dyn,2007;236(4):1144-1156
14 Baylin SB,Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer,2006;6(2):107-116
15 Hatada I.Emerging technologies for genome-wide DNA methylation profiling in cancer. Crit Rev Oncog,2006;12(3-4):205-223
16 Esteller M. Dormant hypermethylated tumour suppressor genes: questions and answers. J Pathol,2005;205(2):172-180
17 Plass C,Smiraglia DJ.Genome-wide analysis of DNA methylation changes in human malignancies. Curr Top Microbiol Immunol,2006;310:179-198
18 Herman JG. Epigenetic changes in cancer and preneoplasia. Cold Spring Harb Symp Quant Biol,2005;70:329-333
19 Ballestar E, Esteller M. The impact of chromatin in human cancer: linking DNA methylation to gene silencing. Carcinogenesis,2002;23(7):1103–1109
20 Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet,2002;3(6):415–428
21 Nephew KP, Huang TH-M. Epigenetic gene silencing in cancer initiation and progression. Cancer Lett,2003;190(2):125–133
22 Baylin SB, Esteller M, Rountree MR, et al. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet,2001;10(7): 687–692
23 Rountree MR, Bachman KE, Herman JG, et al. DNA methylation, chromatin inheritance, and cancer. Oncogene,2001;20(24):3156–3165
24 Maeda G, Chiba T, Aoba T,et al. Epigenetic inactivation of E-cadherin by promoter hypermethylation in oral carcinoma cells. Odontology, 2007;95(1):24-29
25 Mueller W, Nutt CL, Ehrich M,et al. Downregulation of RUNX3 and TES by hypermethylation in glioblastoma. Oncogene, 2007;26(4):583-593
26 Ferres-Marco D,Gutierrez-Garcia I,Vallejo DM,et al.Epigenetic silencers and Notch collaborate to promote malignant tumours by Rb silencing. Nature,2006;439(7075): 430-436
27 Aguilera O, Fraga MF, Ballestar E,et al. Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer.Oncogene, 2006;25(29): 4116-4121
28 Zhu X, Leav I, Leung YK, et al. Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis. Am J Pathol. 2004,164(6):2003-2012
29 Szyf M,Detich N.Regulation of the DNA methylation machinery and its role incellular transformation. Prog Nucleic Acid Res Mol Biol,2001;69:47-79
30 Ogino S, Kawasaki T, Kirkner GJ,et al. 18q loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative (CIMP-0) and inversely with CIMP-low and CIMP-high.BMC Cancer,2007;7:72
31 Goel A,Nagasaka T,Arnold CN,et al.The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer.Gastro- enterology,2007;132(1):127-138
32 Ogino S, Kawasaki T, Ogawa A,et al.TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer.Hum Pathol, 2007;38(4):614-620
33 Kang S, Lee JM, Jeon ES,et al. RASSF1A hypermethylation and its inverse correlation with BRAF and/or KRAS mutations in MSI-associated endometrial carcinoma.Int J Cancer,2006;119(6):1316-1321
34 Noda H, Kato Y, Yoshikawa H,et al.Microsatellite instability caused by hMLH1 promoter methylation increases with tumor progression in right-sided sporadic colorectal cancer.Oncology,2005;69(4):354-362
35 Park HW, Kang HC, Kim IJ,et al.Correlation between hypermethylation of the RASSF2A promoter and K-ras/BRAF mutations in microsatellite-stable colorectal cancers.Int J Cancer,2007;120(1):7-12
36 Murrell A, Rakyan VK, Beck S. From genome to epigenome. Hum Mol Genet,2005; 14(1):R3-R10
37廖锦民.甲基化寡聚核苷酸作为靶基因抑制剂的研究进展.生命科学,1993;5(1):17-19
38熊克勇.用甲基化的寡聚核苷酸做反义制剂.生物工程进展,1992;12(1):15-19
39 Hashimoto S, Sakai M,Muramatsu M. 2'-O-methylated oligonucleotides in ribosomal
18S and 28S RNA of a mouse hepatoma, MH 134. Biochemistry,1975;14(9):1956- 1964
40于海文,吴泰璜,穆庆龄,等.HGF甲基化寡核苷酸对肝癌细胞系BEL-7402作用的研究.中国现代普通外科进展,2004;7(2):93-97
41李文欢,崔屹,朱菊人.甲基化寡核苷酸抑制MRP2表达逆转人肝癌细胞HepG2多药耐药的研究.癌症,2004;23(8):900-904
1汪建平,元云飞.结直肠癌DNA甲基化研究的现状.中华实验外科杂志,2004;21(10): 1279-1280
2陆嵘,房静远.表观遗传修饰与肿瘤.生命科学,2006;18(1):10-14
3 Bos JL,Fearon ER,Hamilton SR,et al.Prevalence of ras gene mutations in human colorectal cancers. Nature,1987;327(6120):293–297
4 Guan R J,Fu Y,Holt P R,et al.Association of K-ras mutations with p16 methylation in human coloncancer.Gastroenterology,1999;116(5):1063-1071
5 Van Engeland M,Roemen GM,Brink M,et al.K-ras mutations and RASSF1A promoter methylation in colorectal cancer. Oncogene,2002;21(23):3792-3795
6 Sikora K,Chan S,Evan G,et al. c-myc oncogene expression in colorectal cancer. Cancer,1987;59(7):1289-1295
7 Sharrard RM,Royds JA,Rogers S,et al.Patterns of methylation of the c-myc gene in human colorectal cancer progression. Br J Cancer,1992;65(5):667-672
8 Sardi I,Dal Canto M,Bartoletti R, et al.Abnormal c-myc oncogene DNA methylation in human bladder cancer:possible role in tumor progression.EurUrol,1997;31(2): 224-230
9 Roa JC,Roa I,Melo A,et al.p53 gene mutation in cancer of the colon and rectum. Rev Med Chil,2000;128(9):996-1004
10 Samowitz WS,Curtin K,Ma KN,et al. Prognostic significance of p53 mutations in colon cancer at the population level. Int J Cancer,2002;99(4):597-602
11 Paluszkiewicz P,Berbec H, Pawlowska-Wakowicz B,et al.p53 protein accumulation in colorectal cancer tissue has prognostic value only in left-sided colon tumours.Cancer Detect Prev,2004;28(4):252-259
12 Oshiro MM,Watts GS,Wozniak RJ,et al.Mutant p53 and aberrant cytosine methylation cooperate to silence gene expression. Oncogene,2003;22(23):3624-3634
13 Esteller M,Sparks A,Toyota M,et al.Analysis of asenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res,2000;60(16):4366-4371
14 Arnold CN,Goel A,Niedzwiecki D,et al.APC promoter hypermethylation contributes to the loss of APC expression in colorectal cancers with allelic loss on 5q. Cancer Biol Ther,2004;3(10):960-964
15 Guoren Deng,Geun-Am Song,Erik Pong,et al.Promoter Methylation Inhibits APC Gene Expression by Causing Changes in Chromatin Conformation and Interfering with the Binding of Transcription Factor CCAAT-Binding Factor.CancerResearch,2004; 64(8):2692-2698
16 Deng G, Song GA, Pong E, et al.Promoter Methylation Inhibits APC Gene Expression by Causing Changes in Chromatin Conformation and Interfering with the Binding of Transcription Factor CCAAT-Binding Factor. Cancer Res, 2004;64(8):2692-2698
17 Jie C,Christoph R,Cathy LD,et al.Molecular analysis of APC promoter methylation and protein expression in colorectal cancer metastasis. Carcinogenesis,2005;26(1): 37-43
18 Kim BN,Yamamoto H,Ikeda K,et al.Methylation and expression of p16INK4 tumorsuppressor gene in primary colorectal cancer tissues.Int J Oncol,2005;26(5): 1217-1226
19 Norrie MW,Hawkins NJ,Todd AV,et al.Inactivation of p16INK4a by CpG hypermehylation is not a frequent event in colorectal cancer. J Surg Oncol,2003; 84(3):143-150
20 Wagner KJ,Cooper WN,Grundy RG,et al.Frequent RASSF1A tumour suppressor gene promoter methylation in Wilms' tumour and colorectal cancer.Oncogene,2002;21(47): 7277-7282
21 Liu T,Tannergard P,Hackman P,et al.Missense mutations in hMLH1 associated with colorectal cancer. Hum Genet,1999;105(5):437-441
22 Kim JC,Kim HC,Roh SA,et al.hMLH1 and hMSH2 mutations in families with familial clustering of gastric cancer and hereditary non-polyposis colorectal cancer. Cancer Detect Prev,2001;25(6) :503-510
23 Noda H,Kato Y,Yoshikawa H,et al.Microsatellite instability caused by hMLH1 promoter methylation increases with tumor progression in right-sided sporadic colorectal cancer.Oncology,2005;69(4):354-362
24 Fiorelli G,Picariello L,Martineti V,et al. Functional estrogen receptor beta in colon cancer cells. Biochem Biophys Res Commun,1999;261(2):521-527
25 Hsu HH,Cheng SF,Wu CC,et al.Apoptotic effects of over-expressed estrogen receptor-beta on LoVo colon cancer cell is mediated by p53 signalings in a ligand-dependent manner. Chin J Physiol,2006;49(2):110-116
26 Rody A,Holtrich U,Solbach C,et al.Methylation of estrogen receptor beta promoter correlates with loss of ER-beta expression in mammary carcinoma and is an early indication marker in premalignant lesions. Endocr Relat Cancer,2005;12(4):903-916
27 Altundag O,Altundag K,Gunduz M.DNA methylation inhibitor, procainamide, may decrease the tamoxifen resistance by inducing overexpression of the estrogen receptor beta in breast cancer patients. Med Hypotheses,2004;63(4):684-687